Irritable bowel syndrome: The burden and unmet needs in Europe

Digestive and Liver Disease

Volumn 38, Issue 10, 2006, Pages 717-723

  Quigley, E M M ^a   Bytzer, P ^b   Jones, R ^c   Mearin, F ^d  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d CENTRO MÉDICO TEKNON   (Spain)

Author keywords

Europe; Healthcare burden; Irritable bowel syndrome; Quality of life

Indexed keywords

ANTIDIARRHEAL AGENT; BULKING AGENT; LAXATIVE; PSYCHOTROPIC AGENT; SPASMOLYTIC AGENT;

ABDOMINAL SURGERY; CHRONIC DISEASE; DELAYED DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE DURATION; DISTRESS SYNDROME; EUROPE; HEALTH CARE COST; HEALTH CARE NEED; HUMAN; IRRITABLE COLON; JOB PERFORMANCE; MEDICAL CARE; MEDICAL SPECIALIST; PATIENT REFERRAL; PELVIS SURGERY; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; QUALITY OF LIFE; SEX RATIO; SHORT SURVEY; SLEEP DISORDER;

COST OF ILLNESS; EUROPE; HEALTH CARE COSTS; HUMANS; IRRITABLE BOWEL SYNDROME; PREVALENCE; QUALITY OF LIFE;

EID: 33748561834     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2006.05.009     Document Type: Short Survey

References (71)

1. Müller-Lissner S.A., Bollani S., Brummer R.-J., Coremans G., Dapoigny M., Marshall J.K., et al. Epidemiological aspects of irritable bowel syndrome in Europe and North America. Digestion 64 (2001) 200-204
2. Badia X., Mearin F., Balboa A., Baro E., Caldwell E., Cucala M., et al. Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria. Pharmacoeconomics 20 (2002) 749-758
3. Talley N.J., Zinsmeister A.R., and Melton L.J. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 142 (1995) 76-83
4. Hungin A.P., Chang L., Dennis E.H., and Barghout V. Irritable bowel syndrome in the United States: symptom patterns and impact. Aliment Pharmacol Ther 21 (2005) 1365-1375
5. Guilera M., Balboa A., and Mearin F. Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol 100 (2005) 1174-1184
6. Collins S.M., and Barbara G. East meets West: infection, nerves, and mast cells in the irritable bowel syndrome. Gut 53 (2004) 1068-1069
7. Spiller R.C. Estimating the importance of infection in IBS. Am J Gastroenterol 98 (2003) 238-241
8. Hungin A.P., Whorwell P.J., Tack J., and Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 17 (2003) 643-650
9. Akehurst R., and Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 48 (2001) 272-282
10. De Giorgio R., Barbara G., Stanghellini V., Cremon C., Salvioli B., De Ponti F., et al. Diagnosis and therapy of irritable bowel syndrome. Aliment Pharmacol Ther 20 Suppl 2 (2004) 10-22
11. Quartero A, Meineche-Schmidt V, Muris J, Rubin G, de Wit N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005; CD003460.
12. Bommelaer G., Dorval E., Denis P., Czernichow P., Frexinos J., Pelc A., et al. Prevalence of irritable bowel syndrome in the French population according to the Rome I criteria. Gastroenterol Clin Biol 26 (2002) 1118-1123
13. Boekema P.J., van Dam van Isselt E.F., Bots M.L., and Smout A.J. Functional bowel symptoms in a general Dutch population and associations with common stimulants. Neth J Med 59 (2001) 23-30
14. Mearin F., Badia X., Balboa A., Baro E., Caldwell E., Cucala M., et al. Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population. Scand J Gastroenterol 36 (2001) 1155-1161
15. Icks A., Haastert B., Enck P., Rathmann W., and Giani G. Prevalence of functional bowel disorders and related healthcare seeking: a population-based study. Z Gastroenterol 40 (2002) 177-183
16. Kennedy T.M., Jones R.H., Hungin A.P.S., O'Flanagan H., and Kelly P. Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population. Gut 43 (1998) 770-774
17. Baretic M., Bilic A., Jurcic D., Mihanovic M., Sunic-Omejc M., Dorosulic Z., et al. Epidemiology of irritable bowel syndrome in Croatia. Coll Antropol 26 Suppl (2002) 85-91
18. El-Serag H.B. Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Rev Gastroenterol Disord 3 Suppl 2 (2003) S3-S11
19. Hillila M.T., and Farkkila M.A. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment Pharmacol Ther 20 (2004) 339-345
20. Drossman D.A., Corazziari E., Talley N.J., Thompson W.G., and Whitehead W. Rome II: the functional gastrointestinal disorders. 2nd ed. (2000), Degnon Associates, McLean, VA
21. Manning A.P., Thompson W.G., Heaton K.W., and Morris A.F. Towards positive diagnosis of the irritable bowel. Br Med J 2 (1978) 653-654
22. Drossman D.A., Thompson W.G., Talley N.J., Funch-Jensen P., Janssens J., and Whitehead W.E. Identification of sub-groups of functional gastrointestinal disorders. Gastroenterol Int 3 (1990) 159-172
23. Olden K.W. The challenge of diagnosing irritable bowel syndrome. Rev Gastroenterol Disord 3 Suppl 3 (2003) S3-S11
24. Wilson S., Roberts L., Roalfe A., Bridge P., and Singh S. Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract 54 (2004) 495-502
25. Thompson W.G. Gender differences in irritable bowel symptoms. Eur J Gastroenterol Hepatol 9 (1997) 299-302
26. Inadomi J.M., Fennerty M.B., and Bjorkman D. Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 18 (2003) 671-682
27. Mearin F., Roset M., Badia X., Balboa A., Baro E., Ponce J., et al. Splitting irritable bowel syndrome: from original Rome to Rome II criteria. Am J Gastroenterol 99 (2004) 122-130
28. Longstreth G.F., Wilson A., Knight K., Wong J., Chiou C.F., Barghout V., et al. Irritable bowel syndrome, healthcare use, and costs: a U.S. managed care perspective. Am J Gastroenterol 98 (2003) 600-607
29. Fullerton S. Functional digestive disorders (FDD) in the year 2000-economic impact. Eur J Surg 582 (1998) 62-64
30. Camilleri M., and Williams D.E. Economic burden of irritable bowel syndrome proposed strategies to control expenditures. Pharmacoeconomics 4 (2000) 331-338
31. Ricci J.-F. Irritable bowel syndrome: a comparison of the economic (direct and indirect) burden in four European countries. Gut 51 (2002) A107
32. Hahn B., Yan S., and Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion 60 (1999) 77-81
33. Dapoigny M., Dyard F., Grimaud J.C., Guyot P., and van Ganse E. Irritable bowel syndrome and healthcare consumption. An observational study in private gastroenterology. Gastroenterol Clin Biol 27 (2003) 265-271
34. Hunt RH, Dhaliwal S, Tougas G, Pedro C, Labbe J-F, Paul H, et al. Prevalence, impact and attitudes towards treatment of lower gastrointestinal symptoms in Canada: a descriptive study. Can J Gastroenterol, submitted for publication.
35. Le Pen C., Ruszniewski P., Gaudin A.F., Amouretti M., Bommelaer G., Frexinos J., et al. The burden cost of French patients suffering from irritable bowel syndrome. Scand J Gastroenterol 39 (2004) 336-343
36. Müller-Lissner S.A., and Pirk O. Irritable bowel syndrome in Germany. A cost of illness study. Eur J Gastroenterol Hepatol 14 (2002) 1325-1329
37. Kozma C.M., Barghout V., Slaton T., Frech F., and Reeder C.E. A comparison of office-based physician visits for irritable bowel syndrome and for migraine and asthma. Manag Care Interface 15 (2002) 40-43 49
38. Gralnek I.M., Hays R.D., Kilbourne A., Naliboff B., and Mayer E.A. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 119 (2000) 654-660
39. Frank L., Kleinman L., Rentz A., Ciesla G., Kim J.J., and Zacker C. Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther 24 (2002) 675-689
40. Walters S.J., Ward S.E., Akehurst R.L., and Ricci J.-F. Quality of life of IBS patients in the United Kingdom compared with a general population sample. Gastroenterology 124 (2003) A-396
41. Smith G.D., Steinke D.T., Kinnear M., Penny K.I., Pathmanathan N., and Penman I.D. A comparison of irritable bowel syndrome patients managed in primary and secondary care: the Episode IBS study. Br J Gen Pract 54 (2004) 503-507
42. Dapoigny M., Bellanger J., Bonaz B., Bruley des Varannes S., Bueno L., Coffin B., et al. Irritable bowel syndrome in France: a common, debilitating and costly disorder. Eur J Gastroenterol Hepatol 16 (2004) 995-1001
43. Kettell J., Jones R., and Lydeard S. Reasons for consultation in irritable bowel syndrome: symptoms and patient characteristics. Br J Gen Pract 42 (1992) 459-461
44. Drossman D.A., McKee D.C., Sandler R.S., Mitchell C.M., Cramer E.M., Lowman B.C., et al. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology 95 (1988) 701-708
45. Olden K.W. Irritable bowel syndrome: what is the role of the psyche?. Dig Liver Dis 38 (2006) 200-201
46. Delvaux M., and Frexinos J. A European approach to irritable bowel syndrome management. Can J Gastroenterol 13 (1999) 85-88
47. AGA PCC. American Gastroenterological Association medical position statement: irritable bowel syndrome. Gastroenterology 112 (1997) 2118-2119
48. Cash B., Sullivan S., and Barghout V. Total costs of IBS: employer and managed care perspective. Am J Manag Care 11 (2005) S7-S16
49. Longstreth G.F., and Yao J.F. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology 126 (2004) 1665-1673
50. Vandvik P.O., Wilhelmsen I., Ihlebaek C., and Farup P.G. Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications. Aliment Pharmacol Ther 20 (2004) 1195-1203
51. Thompson W.G., Heaton K.W., Smyth G.T., and Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 46 (2000) 78-82
52. ACG, and American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol 97 (2002) S1-S5
53. Valenzuela J., Alvarado J., Cohen H., Damiao A., Francisconi C., Frugone L., et al. Latin-American consensus document on irritable bowel syndrome. Gastroenterol Hepatol 27 (2004) 325-343
54. Malagelada J.R. IBS: making a positive diagnosis. Int J Clin Pract 60 (2006) 57-63
55. Paterson W.G., Thompson W.G., Vanner S.J., Faloon T.R., Rosser W.W., Birtwhistle R.W., et al. Recommendations for the management of irritable bowel syndrome in family practice. Can Med Assoc J 161 (1999) 154-160
56. Veldhuyzen van Zanten S.J. Diagnosing irritable bowel syndrome. Rev Gastroenterol Disord 3 Suppl 2 (2003) S12-S17
57. Fennerty M.B. Traditional therapies for irritable bowel syndrome: an evidence-based appraisal. Rev Gastroenterol Disord 3 Suppl 2 (2003) S18-S24
58. Bazzocchi G., Gionchetti P., Almerigi P.F., Amadini C., and Campieri M. Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Dig Liver Dis 34 Suppl 2 (2002) S48-S53
59. Kim H.J., Camilleri M., McKinzie S., Lempke M.B., and Burton D.D. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 17 (2003) 895-904
60. Atkinson W., Sheldon T.A., Shaath N., and Whorwell P.J. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 53 (2004) 1459-1464
61. Drossman D.A., Toner B.B., Whitehead W.E., Diamant N.E., Dalton C.B., Duncan S., et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 125 (2003) 19-31
62. Gonsalkorale W.M., and Whorwell P.J. Hypnotherapy in the treatment of irritable bowel syndrome. Eur J Gastroenterol Hepatol 17 (2005) 15-20
63. Bensoussan A., Talley N.J., Hing M., Menzies R., Guo A., and Ngu M. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. J Am Med Assoc 280 (1998) 1585-1589
64. Riotto M. Depression in the workplace: negative effects, perspective on drug costs and benefit solutions. Benefits Q 17 (2001) 37-48
65. Bertram S., Kurland M., Lydick E., Locke III G.R., and Yawn B.P. The patient's perspective of irritable bowel syndrome. J Fam Pract 50 (2001) 521-525
66. Thompson W.G., Heaton K.W., Smyth G.T., and Smyth C. Irritable bowel syndrome: the view from general practice. Eur J Gastroenterol Hepatol 9 (1997) 689-692
67. Lea R., Hopkins V., Hastleton J., Houghton L.A., and Whorwell P.J. Diagnostic criteria for irritable bowel syndrome: utility and applicability in clinical practice. Digestion 70 (2004) 210-213
68. Dapoigny M. Irritable bowel syndrome and the general practioners. Dig Liver Dis 37 (2005) 907-908
69. Jones J., Boorman J., Cann P., Forbes A., Gomborone J., Heaton K., et al. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 47 (2000) 1-19
70. Bellini M., Tosetti C., Costa F., Biagi S., Stasi C., Del Punta A., et al. The general practitioner's approach to irritable bowel syndrome: from intention to practice. Dig Liver Dis 37 (2005) 934-939
71. Quigley E.M. Why do we have so few effective drugs for irritable bowel syndrome? A European perspective. Nat Clin Pract Gastroenterol Hepatol 2 (2005) 436-437